By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Standard & Poor's today raised its corporate credit rating on Bio-Rad Laboratories to "BBB" from "BBB-" with a stable outlook.

The credit rating service also said that it had raised Bio-Rad's senior subordinated rating to "BBB-" from "BB+".

"The upgrade reflects Bio-Rad's continued solid operating performance and cash flow generation, despite recent challenges in the life science industry," S&P Credit Analyst Arthur Wong said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.